BACKGROUND AND PURPOSE: Cerebral amyloid angiopathy (CAA) is common in the ageing brain and is associated with dementia and lobar intracerebral haemorrhage. We systematically reviewed genetic associations with CAA to better understand its pathogenesis. METHODS: We comprehensively sought and critically appraised published studies of associations between any genetic polymorphism and histopathologically confirmed CAA. We assessed the effects of genotype by calculating study specific and pooled odds ratios (ORs) in meta-analyses, and assessed small study bias. RESULTS: 58 studies (6855 participants) investigated apolipoprotein E (APOE) genotype and sporadic CAA. Meta-analysis of 24 (3520 participants) of these showed an association of APOE ε4 with CAA (ε4 present vs absent, pooled OR 2.7, 95% CI 2.3 to 3.1, p<0.00001), which was dose dependent, robust to potential small study biases and occurred irrespective of dementia status. There was no significant association between APOE ε2 and CAA. Among 24 studies (4703 participants) of other genetic polymorphisms, there was preliminary evidence of an association with CAA of polymorphisms in the transforming growth factor β1 gene (two studies, 449 participants), translocase of outer mitochondrial membrane 40 gene (one study, 723 participants) and the complement component receptor 1 gene (one study, 544 participants). There were insufficient data to draw conclusions from 24 studies (∼200 participants) of APOE and hereditary CAA or familial Alzheimer's disease. CONCLUSIONS: There is convincing evidence for a dose dependent association between APOE ε4 and sporadic CAA. Further work is needed to better understand the mechanism of this association and to further investigate other genetic associations with CAA.
BACKGROUND AND PURPOSE:Cerebral amyloid angiopathy (CAA) is common in the ageing brain and is associated with dementia and lobar intracerebral haemorrhage. We systematically reviewed genetic associations with CAA to better understand its pathogenesis. METHODS: We comprehensively sought and critically appraised published studies of associations between any genetic polymorphism and histopathologically confirmed CAA. We assessed the effects of genotype by calculating study specific and pooled odds ratios (ORs) in meta-analyses, and assessed small study bias. RESULTS: 58 studies (6855 participants) investigated apolipoprotein E (APOE) genotype and sporadic CAA. Meta-analysis of 24 (3520 participants) of these showed an association of APOE ε4 with CAA (ε4 present vs absent, pooled OR 2.7, 95% CI 2.3 to 3.1, p<0.00001), which was dose dependent, robust to potential small study biases and occurred irrespective of dementia status. There was no significant association between APOE ε2 and CAA. Among 24 studies (4703 participants) of other genetic polymorphisms, there was preliminary evidence of an association with CAA of polymorphisms in the transforming growth factor β1 gene (two studies, 449 participants), translocase of outer mitochondrial membrane 40 gene (one study, 723 participants) and the complement component receptor 1 gene (one study, 544 participants). There were insufficient data to draw conclusions from 24 studies (∼200 participants) of APOE and hereditary CAA or familial Alzheimer's disease. CONCLUSIONS: There is convincing evidence for a dose dependent association between APOE ε4 and sporadic CAA. Further work is needed to better understand the mechanism of this association and to further investigate other genetic associations with CAA.
Authors: John M Ringman; Michael C Sachs; Yan Zhou; Sarah E Monsell; Jeffrey L Saver; Harry V Vinters Journal: JAMA Neurol Date: 2014-07-01 Impact factor: 18.302
Authors: Mafalda Cacciottolo; Amy Christensen; Alexandra Moser; Jiahui Liu; Christian J Pike; Conor Smith; Mary Jo LaDu; Patrick M Sullivan; Todd E Morgan; Egor Dolzhenko; Andreas Charidimou; Lars-Olof Wahlund; Maria Kristofferson Wiberg; Sara Shams; Gloria Chia-Yi Chiang; Caleb E Finch Journal: Neurobiol Aging Date: 2015-10-19 Impact factor: 4.673
Authors: Eva Martínez-Lizana; María Carmona-Iragui; Daniel Alcolea; Manuel Gómez-Choco; Eduard Vilaplana; María B Sánchez-Saudinós; Jordi Clarimón; Mar Hernández-Guillamon; Josep Munuera; Ellen Gelpi; Beatriz Gómez-Anson; Manel de Juan-Delago; Raquel Delgado-Mederos; Joan Montaner; Angel Ois; Sergi Amaro; Rafael Blesa; Joan Martí-Fàbregas; Alberto Lleó; Juan Fortea Journal: J Cereb Blood Flow Metab Date: 2015-03-04 Impact factor: 6.200
Authors: María Carmona-Iragui; Mircea Balasa; Bessy Benejam; Daniel Alcolea; Susana Fernández; Laura Videla; Isabel Sala; María Belén Sánchez-Saudinós; Estrella Morenas-Rodriguez; Roser Ribosa-Nogué; Ignacio Illán-Gala; Sofía Gonzalez-Ortiz; Jordi Clarimón; Frederick Schmitt; David K Powell; Beatriz Bosch; Albert Lladó; Michael S Rafii; Elizabeth Head; José Luis Molinuevo; Rafael Blesa; Sebastián Videla; Alberto Lleó; Raquel Sánchez-Valle; Juan Fortea Journal: Alzheimers Dement Date: 2017-04-29 Impact factor: 21.566
Authors: Andreas Charidimou; Sergi Martinez-Ramirez; Ashkan Shoamanesh; Jamary Oliveira-Filho; Matthew Frosch; Anastasia Vashkevich; Alison Ayres; Jonathan Rosand; Mahmut Edip Gurol; Steven M Greenberg; Anand Viswanathan Journal: Neurology Date: 2015-02-25 Impact factor: 9.910